(79 days)
Not Found
No
The document explicitly states, "The PIPS does not include any automated image analysis applications that would constitute computer aided detection or diagnosis." and there are no mentions of AI, DNN, or ML.
No
The device aids pathologists in diagnosing diseases by providing a system for viewing digital pathology slides, but it does not directly treat or alleviate a medical condition.
Yes
The device is explicitly stated as "intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides."
No
The device description explicitly states that the PIPS 5.1 system comprises hardware components including scanners (Ultra Fast Scanner, Pathology Scanner SG models) and clinical displays (PP27QHD, C411W, or MDCC-4430), in addition to the Image Management System (IMS) software.
Yes, the Philips IntelliSite Pathology Solution (PIPS) 5.1 is an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the PIPS 5.1 is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides.
- Purpose: The device is used to create, view, and manage digital images of biological specimens (tissue slides) for the purpose of diagnosis by a qualified pathologist. This aligns with the definition of an in vitro diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic purposes.
N/A
Intended Use / Indications for Use
The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. The PIPS 5.1 is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS 5.1 is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.
The PIPS 5.1 comprises the Imagement System (IMS) 4.2, Ultra Fast Scanner (UFS), Pathology Scanner SG20. Pathology Scanner SG60, Pathology Scanner SG300 and Philips PP27QHD display, a Beacon C411W display or a Barco MDCC-4430 display. The PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS 5.1.
Product codes
PSY
Device Description
The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. PIPS 5.1 consists of two subsystems and a display component:
-
- A scanner in any combination of the following scanner models
- . Ultra Fast Scanner (UFS)
- Pathology Scanner SG with different versions for varying slide capacity . Pathology Scanner SG20, Pathology Scanner SG60, Pathology Scanner SG300
-
- Image Management System (IMS) 4.2
-
- Clinical display
- PP27QHD or C411W or MDCC-4430 .
PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. The PIPS does not include any automated image analysis applications that would constitute computer aided detection or diagnosis. The pathologists only view the scanned images and utilize the image review manipulation software in the PIPS 5.1.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Scanned glass slides
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Pathologist, for in vitro diagnostic use.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Non-clinical performance testing was performed on the display of the proposed device to demonstrate compliance with international and FDA-recognized consensus standards (IEC 60601-1 Ed 3.2, IEC 60601-1-6, IEC 62471:2006, ISO 14971:2019). Following the TPA guidance, a sub-set of tests were performed to verify that the technological characteristics of the display were not affected by the new panel. These tests included: Spatial resolution, Pixel defects, Artifacts, Temporal response, Maximum and minimum luminance, Grayscale, Luminance uniformity, Stability of luminance and chromaticity, Bidirectional reflection distribution function, Grav tracking, Color scale response, and Color gamut volume.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
The change of the display of the proposed device is within the controls and predetermined specifications.
§ 864.3700 Whole slide imaging system.
(a)
Identification. The whole slide imaging system is an automated digital slide creation, viewing, and management system intended as an aid to the pathologist to review and interpret digital images of surgical pathology slides. The system generates digital images that would otherwise be appropriate for manual visualization by conventional light microscopy.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Premarket notification submissions must include the following information:
(i) The indications for use must specify the tissue specimen that is intended to be used with the whole slide imaging system and the components of the system.
(ii) A detailed description of the device and bench testing results at the component level, including for the following, as appropriate:
(A) Slide feeder;
(B) Light source;
(C) Imaging optics;
(D) Mechanical scanner movement;
(E) Digital imaging sensor;
(F) Image processing software;
(G) Image composition techniques;
(H) Image file formats;
(I) Image review manipulation software;
(J) Computer environment; and
(K) Display system.
(iii) Detailed bench testing and results at the system level, including for the following, as appropriate:
(A) Color reproducibility;
(B) Spatial resolution;
(C) Focusing test;
(D) Whole slide tissue coverage;
(E) Stitching error; and
(F) Turnaround time.
(iv) Detailed information demonstrating the performance characteristics of the device, including, as appropriate:
(A) Precision to evaluate intra-system and inter-system precision using a comprehensive set of clinical specimens with defined, clinically relevant histologic features from various organ systems and diseases. Multiple whole slide imaging systems, multiple sites, and multiple readers must be included.
(B) Reproducibility data to evaluate inter-site variability using a comprehensive set of clinical specimens with defined, clinically relevant histologic features from various organ systems and diseases. Multiple whole slide imaging systems, multiple sites, and multiple readers must be included.
(C) Data from a clinical study to demonstrate that viewing, reviewing, and diagnosing digital images of surgical pathology slides prepared from tissue slides using the whole slide imaging system is non-inferior to using an optical microscope. The study should evaluate the difference in major discordance rates between manual digital (MD) and manual optical (MO) modalities when compared to the reference (
e.g., main sign-out diagnosis).(D) A detailed human factor engineering process must be used to evaluate the whole slide imaging system user interface(s).
(2) Labeling compliant with 21 CFR 809.10(b) must include the following:
(i) The intended use statement must include the information described in paragraph (b)(1)(i) of this section, as applicable, and a statement that reads, “It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using this device.”
(ii) A description of the technical studies and the summary of results, including those that relate to paragraphs (b)(1)(ii) and (iii) of this section, as appropriate.
(iii) A description of the performance studies and the summary of results, including those that relate to paragraph (b)(1)(iv) of this section, as appropriate.
(iv) A limiting statement that specifies that pathologists should exercise professional judgment in each clinical situation and examine the glass slides by conventional microscopy if there is doubt about the ability to accurately render an interpretation using this device alone.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue box, followed by the words "U.S. FOOD & DRUG" in a larger, bold blue font. Below that is the word "ADMINISTRATION" in a smaller, blue font.
Philips Medical Systems Nederland B.V. Donna Peled Head of Regulatory Affairs - Clinical Informatics Veenpluis 6 Best. 5684 PC Netherlands
March 6, 2025
Re: K243871
Trade/Device Name: Philips IntelliSite Pathology Solution 5.1 Regulation Number: 21 CFR 864.3700 Regulation Name: Whole slide imaging system Regulatory Class: Class II Product Code: PSY Dated: December 17, 2024 Received: December 17, 2024
Dear Donna Peled:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrb/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
1
2
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
2
Sincerely,
Shyam Kalavar -S
Shyam Kalavar Deputy Branch Chief Division of Molecular Genetics and Pathology OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K243871
Device Name Philips IntelliSite Pathology Solution 5.1
Indications for Use (Describe)
The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. The PIPS 5.1 is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS 5.1 is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.
The PIPS 5.1 comprises the Imagement System (IMS) 4.2, Ultra Fast Scanner (UFS), Pathology Scanner SG20. Pathology Scanner SG60, Pathology Scanner SG300 and Philips PP27QHD display, a Beacon C411W display or a Barco MDCC-4430 display. The PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS 5.1.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
C)
4
510(K) SUMMARY
This 510(k) summary of safety and effectiveness information is prepared in accordance with 21 CFR §807.92.
1.1 General information
March 05, 2025
1.1.1 Company identification
Philips Medical Systems Nederland B.V. Veenpluis 6 5684 PC Best The Netherlands Registration number: 3012563754
1.1.2 Contact Person
Donna Peled Head of Regulatory Affairs - Clinical Informatics Digital & Computational Pathology Phone: +972-52-6145353 Email: donna.peled@philips.com
Identification of the device and classification 1.1.3
Device trade name: Philips IntelliSite Pathology Solution 5.1 510(k) number: K243871 Device Class: Class II Classification regulation: 864.3700 Product code: PSY Classification name: Whole Slide Imaging System Classification panel: Pathology
1.1.4 Legally marketed predicate devices to which substantial equivalence is claimed
Device trade name: Philips IntelliSite Pathology Solution 5.1 510(k) number: K242848 Device Class: Class II CFR section: 864.3700 Product code PSY Classification name: Whole Slide Imaging System Classification panel: Pathology
5
1.2 Device description
The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. PIPS 5.1 consists of two subsystems and a display component:
-
- A scanner in any combination of the following scanner models
- . Ultra Fast Scanner (UFS)
- Pathology Scanner SG with different versions for varying slide capacity . Pathology Scanner SG20, Pathology Scanner SG60, Pathology Scanner SG300
-
- Image Management System (IMS) 4.2
-
- Clinical display
- PP27QHD or C411W or MDCC-4430 .
PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. The PIPS does not include any automated image analysis applications that would constitute computer aided detection or diagnosis. The pathologists only view the scanned images and utilize the image review manipulation software in the PIPS 5.1.
1.2.1 Intended use
Compared to the predicate device the Intended Use / Indications for Use statement of the subject device has been updated to reflect the new Barco MDCC-4430 display. The Intended use remains unchanged.
The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. The PIPS 5.1 is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS 5.1 is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.
The PIPS 5.1 comprises the Imagement System (IMS) 4.2. Ultra-Fast Scanner (UFS), Pathology Scanner SG20, Pathology Scanner SG60, Pathology Scanner SG300 and Philips PP27QHD display, a Beacon C411W display or a Barco MDCC-4430 display. The PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS 5.1.
1.2.2 Comparison of technological characteristics with the predicate device
The proposed device has the same technological characteristics compared to the predicate device, with the exception of the following minor modification implemented in the proposed device: Introduction of a new clinical display, MDCC-4430, as an alternative option for the predicate display, PP27QHD.
The proposed device will employ display MDCC-4430 from manufacturer Barco as an option for the current predicate display. The new display has similar technological characteristics and pixel resolution as compared to the predicate device. Table 1.1 below describes the modified technological characteristics for the new display in accordance with FDA's Guidance for Industry
6
and FDA Staff entitled, "Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices" (hereafter referred to as TPA Guidance), dated April 20, 2016.
Other TPA guidance items related to the display are not impacted by the new display and remain identical to the predicate device.
| TPA Description | | Predicate device
(K242848) | Subject device | Conclusion on substantial
equivalence |
|-------------------------------------------------------------------|--------------------------|-----------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Technological
characteristics
of the display
device | Display type | Color LCD | | Substantially equivalent:
The minor difference in the
physical display size is a
minor change and does not
raise any questions of safety
or effectiveness. |
| | Manufacturer | Barco N.V. | | |
| | Technology | IPS
technology
with a-Si
Thin Film
Transistor | unchanged | Conclusion: The proposed
and predicate device are
considered substantially
equivalent. |
| | Physical
display size | $648.5 mm x423 mm x91.3 mm(withbacklightdisc)$ | $714 mm x478 mm x 74mm$ | |
| Physical size
of the
viewable area
and aspect
ratio | Active
display area | $596.74 mmx 355.66mm(27.0 inchdiagonal)$ | $655 mm x410 mm(30.4 inchdiagonal)$ | Substantially equivalent:
The slightly higher viewable
area for the new display with
respect to the predicate
device is a minor change.
Verification testing confirms
that the image quality of the
display is equivalent to the
predicate device. |
| | Aspect ratio | 16:9 | 16:10 | Conclusion: This change
does not raise any new
concerns on safety and
effectiveness. The proposed
and predicate device are
considered substantially
equivalent. |
| Pixel array,
pitch,
pixel aperture
ratio and
subpixel | Resolution | $2560 x 1440pixels$ | $2560 x 1600pixels$ | Substantially equivalent:
The slightly higher resolution
and pixel size for the new
display with respect to the
predicate device is a minor |
| | Pixel Pitch | $0.2331 mmx 0.2331mm$ | $0.256 mm x0.256 mm$ | |
| Table 1.1 | Modified technological characteristics for the display |
|---|---|
| ----------- | -------------------------------------------------------- |
7
| TPA Description | Predicate device (K242848) | Subject device | Conclusion on substantial equivalence |
|---|---|---|---|
| matrix scheme | change. Verification testing confirms that the image quality is equivalent to the predicate device. | ||
| Conclusion: This change does not raise any new concerns on safety and effectiveness. The proposed and predicate device are considered substantially equivalent. | |||
| Color calibration tools (sensor hardware and associated software) | Calibration software | ||
| MediCal QAWeb Agent software version 1.13.12 installed on the workstation | QAWeb Enterprise version 2.14.0 installed on the workstation | Substantially equivalent: The new display employs different calibration software in comparison with the predicate device. The calibration method (via built in front sensor), calibration targets and frequency of quality control tests remains | |
| Calibration hardware | |||
| Build in front sensor | Same | unchanged. | |
| Conclusion: This change does not raise any new concerns on safety and effectiveness. The proposed and predicate device are considered substantially equivalent. |
1.3 Summary of non-clinical performance data
Non-clinical performance testing was performed on the display of the proposed device and demonstrates compliance with the following international and FDA-recognized consensus standards:
- IEC 60601-1 Edition 3.2 (2020) Medical electrical equipment Part 1: General . requirements for basic safety and essential performance
- IEC 60601-1-6 (4th Ed) Medical electrical equipment Part 1-6: General requirements ● for basic safety and essential performance - Collateral Standard: Usability
- . IEC 62471:2006 Photobiological safety of lamps and lamp systems
- . ISO 14971:2019 Medical devices - Application of risk management to medical devices
8
Following the TPA guidance, the below mentioned sub-set of tests were performed to verify that the technological characteristics of the display were not affected by the new panel.
- Spatial resolution .
- . Pixel defects
- . Artifacts
- Temporal response ●
- Maximum and minimum luminance ●
- Grayscale
- Luminance uniformity ●
- Stability of luminance and chromaticity ●
- Bidirectional reflection distribution function
- . Grav tracking
- Color scale response ●
- Color gamut volume. ●
In addition, the existing functional, safety and system integration requirements related to the display were verified.
Conclusion:
The verification for the new display showed that the proposed device has similar technological characteristics compared to the predicate device following the TPA guidance and is in compliance with aforementioned international and FDA-recognized consensus standards. Verification and validation of the existing safety, user and system integration requirements showed that the proposed PIPS 5.1 with the new clinical display is safe and effective. The proposed device conforms to its intended use and user needs. Therefore, the proposed device with the new clinical display is substantially equivalent to the predicate device in terms of safety and effectiveness.
1.4 Summary of clinical performance data
The proposed device with the new display did not require clinical performance data since substantial equivalence to the currently marketed predicate device was demonstrated with the following attributes:
- Intended Use / Indications for Use,
- Technological characteristics, ●
- . Non-clinical performance testing, and
- Safety and effectiveness .
These attributes demonstrated that the clinical performance of the modified device is substantially equivalent to the predicate device.
1.5 Conclusion
The proposed PIPS 5.1 with a new clinical display as option for the current display is substantially equivalent to the predicate device in terms of Intended Use/Indications for Use, technological characteristics, and safety and effectiveness.
The change of the display of the proposed device is within the controls and predetermined specifications. Additionally, non-clinical performance tests (bench testing) ensured that the modifications are properly introduced. These tests were used to support substantial equivalence of the proposed device and demonstrated that it is as safe and effective as its predicate device without raising any new safety and/or effectiveness concerns.